{
  "docId": "019de512-188f-75bd-b9c3-b699923bd74c",
  "docSlug": "b87a8eceb8fdc0b05f41052c19d68b16",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 19,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 40,
  "notes": "The table uses a color-coded scale to represent potency (IC50), where red indicates higher potency (lower IC50) and white/grey indicates lower potency.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de512-188f-75bd-b9c3-b699923bd74c/11",
  "deckHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c",
  "deckJsonHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c.json",
  "deckAnchorHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.12,
        "x": 0.83,
        "y": 0.24
      },
      "kind": "chart",
      "text": "IC50 legend",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "021139f3-a6c1-46e6-ad3f-538c59b0b518",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "There are no head-to-head trials between ADG20 and the other products referenced on this slide. No comparisons can be made between product efficacy or safety. ADG20 is an investigational therapy that is not approved for use in any country.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e1e1436-40e9-49e8-99b8-19f3759feb79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.2,
        "y": 0.25
      },
      "kind": "table",
      "text": "Heatmap of IC50 values for antibodies (ADG20, S309, REGN10933, REGN10987, LY-CoV555, LY-CoV16, AZD1061, AZD8895) against variants (Victoria, Alpha, Beta, Gamma, Delta)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77819790-9626-4d70-8fc6-37639d540931",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "ADG20 shows broad yet variable neutralizing activity against all variants of concern",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef3ac96d-792e-430b-b538-eb79d1ce80c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "In vitro neutralization of antibodies in clinical development versus variants of concern",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba2b9cb3-b6c4-4952-9e54-cf3dfe1440e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Heatmap matrix",
      "slug": "heatmap-matrix",
      "agent": null,
      "layer": "slide",
      "matchId": "fa403a4a-bed2-4ee1-be88-8a026f10fec7",
      "evidence": "Heatmap of IC50 values for antibodies (ADG20, S309, REGN10933, REGN10987, LY-CoV555, LY-CoV16, AZD1061, AZD8895) against variants (Victoria, Alpha, Beta, Gamma, Delta)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "6a1a205b-c7b3-4004-94f2-1eab1f50d86f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem through multiple tables and data points, highlighting the challenge of COVID-19 variants.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "367a8c0e-d39d-4694-aace-945e8b5a0e36",
      "evidence": "The document implies the cost of inaction through its emphasis on the challenge of COVID-19 variants and the need for effective treatments.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}